AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
265.08
-0.13 (-0.05%)
At close: Sep 23, 2026, 4:00 PM EDT
262.42
-2.66 (-1.00%)
After-hours: Sep 23, 2026, 4:38 PM EDT
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,129,579
Profits / Employee
$110,000
Market Cap
468.43B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 1 day ago - Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach - PRNewsWire
- 1 day ago - AbbVie: EC approves Rinvoq to treat polyarticular juvenile idiopathic arthritis - TheFly
- 1 day ago - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis - PRNewsWire
- 2 days ago - AbbVie, Iambic announce multi-year collaboration - TheFly
- 2 days ago - AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery - PRNewsWire
- 5 days ago - AbbVie presents new Vraylar data at Psych Congress 2026 - TheFly
- 5 days ago - AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026 - PRNewsWire
- 6 days ago - AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting - PRNewsWire